AstraZeneca Pharma India Ltd. - Q2 FY26 Financial Performance & Investor Update

AstraZeneca Pharma India Ltd. has announced exceptional financial results for the second quarter ended September 30, 2025 (Q2 FY26). The period was characterized by significant, broad-based growth, underscoring strong operational execution and robust market demand. 1. Executive Summary: Robust Growth & Profitability The company delivered a strong performance, achieving a 41.1% year-on-year (YoY) increase in net profit and a 37% increase in revenue. This growth was complemented by a notable expansion in operating margins, reflecting enhanced cost efficiencies and operational leverage. 2. Key Financial Highlights (Q2 FY26 vs. Q2 FY25) Revenue from Operations: The company achieved a 37% YoY increase in revenue, which rose to ₹559 crore from ₹408 crore (implied) in the corresponding period last year. This strong top-line growth is attributed to sustained high demand across the company's key therapeutic areas. Profit After Tax (PAT): Net profit grew robustly by 41.1% YoY to ₹54.2 crore, compared to ₹38.4 crore in Q2 FY25. This substantial bottom-line growth demonstrates the company's strong earning capacity. 3. Operational Performance & Margin Analysis EBITDA Growth: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) surged by 43.7% YoY to ₹75.4 crore, up from ₹52.5 crore. The fact that EBITDA growth outpaced revenue growth highlights significant improvements in operational performance. Margin Expansion: The company's focus on cost efficiency and productivity resulted in an expansion of its operating margins. The operating margin improved to 13.5% in Q2 FY26, a 60-basis-point expansion from 12.9% in the prior-year quarter.